Paragon Biosciences is a biopharmaceutical investment firm being led in part by Jeff Aronin, Chairman and Chief Executive Officer of two of the major branches under this umbrella since 2010. The company is growing by leaps and bounds. In fact, it has received FDA approval on 13 new medications over the course of less than a decade. This is a pace of approval typically only applicable to the largest of pharmaceutical companies. This pace, however, does not mean that the humanity and true purpose behind the company goals is compromised at all. Every patient is part of a meticulous collaborative effort between doctor and patient where their respective value is made apparent.
Prior to his employment with Paragon Biosciences, Jeff Aronin was President and CEO of Ovation Pharmaceuticals, Inc. He founded the company in 2000 and ran it successfully until 2009 when Ovation Pharmaceuticals was acquired by Lundbeck, Inc. After the takeover, Aronin remained in place during the acquisition and integration by Lundbeck to ensure the best possible results.
With two decades of experience in the industry of biotechnology, Jeff Aronin has developed a distinctive knowledge of rare disorders, exceptionally complex research methodology, and the process by which new medications are created. Aronin recognized how incredibly precious time is to those who are terminal and Paragon Biosciences makes ample funds available for research teams to develop cutting edge medications for incurable diseases.
Both Jeff Aronin and Paragon Biosciences as a whole draw inspiration from the arc of technological innovation. Advances in technology have driven profound changes in the amazing feats that can be accomplished in current times. Additionally, associated costs with technology have become more reasonable as advances are made. This progression of technology pushes Aronin and Paragon forward to utilize these technological advances to the highest and best potential use.